Clinical performance of the new Roche COBAS® TaqMan HCV Test and High Pure System for extraction, detection and quantitation of HCV RNA in plasma and serum

Antiviral Therapy

Volumn 11, Issue 1, 2006, Pages 95-103

  Gelderblom, Huub C ^a   Menting, Sandra ^a   Beld, Marcel G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; EXTRACTION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PERFORMANCE; PLASMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SERUM; VIRUS DETECTION;

BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; HEPACIVIRUS; HEPATITIS C; HUMANS; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TAQ POLYMERASE;

EID: 33644523760     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38:645-652.
2. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-87.
3. Sarrazin C, Hendricks DA, Sedarati F, Zeuzem S. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol 2001; 39:2850-2855.
4. Sarrazin C, Teuber G, Kokka R, Rabenau H, Zeuzem S. Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology 2000; 32:818-823.
5. Barbeau JM, Goforth J, Caliendo AM, Nolte FS. Performance characteristics of a quantitative TaqMan hepatitis C virus RNA analyte-specific reagent. J Clin Microbiol 2004; 42:3739-3746.
6. Castelain S, Descamps V, Thibault V, et al. TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol 2004; 31:227-234.
7. Cook L, Ng KW, Bagabag A, Corey L, Jerome KR. Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA. J Clin Microbiol 2004; 42:4130-4136.
8. Enomoto M, Nishiguchi S, Shiomi S, et al. Comparison of real-time quantitative polymerase chain reaction with three other assays for quantitation of hepatitis C virus. J Gastroenterol Hepatol 2001; 16:904-909.
9. Forman MS, Valsamakis A. Verification of an assay for quantification of hepatitis C virus RNA by use of an analyte-specific reagent and two different extraction methods. Journal of Clinical Microbiology 2004; 42:3581-3588.
10. Germer JJ, Harmsen WS, Mandrekar JN, Mitchell PS, Yao JD. Evaluation of the COBAS TaqMan HCV test with automated sample processing using the MagNA pure LC instrument. J Clin Microbiol 2005; 43:293-298.
11. Kawai S, Yokosuka O, Kanda T, Imazeki F, Maru Y, Saisho H. Quantification of hepatitis C virus by TaqMan PCR: comparison with HCV Amplicor Monitor assay. J Med Virol 1999; 58:121-126.
12. Kleiber J, Walter T, Haberhausen G, Tsang S, Babiel R, Rosenstraus M. Performance characteristics of a quantitative, homogeneous TaqMan RT-PCR test for HCV RNA. J Mol Diagn 2000; 2:158-166.
13. Morris T, Robertson B, Gallagher M. Rapid reverse transcription-PCR detection of hepatitis C virus RNA in serum by using the TaqMan fluorogenic detection system. J Clin Microbiol 1996; 34:2933-2936.
14. Puig M, Mihalik K, Yu MY, Feinstone SM, Major ME. Sensitivity and reproducibihty of HCV quantitation in chimpanzee sera using TaqMan real-time PCR assay. J Virol Methods 2002; 105:153-263.
15. Beld M, Sentjens R, Rebers S, et al. Performance of the New Bayer VERSANT HCV RNA 3.0 assay for quantitation of hepatitis C virus RNA in plasma and serum: conversion to international units and comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, assay. J Clin Microbiol 2002; 40:788-793.
16. Elbeik T, Surtihadi J, Destree M, et al. Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol 2004; 42:563-569.
17. Germer JJ, Heimgartner PJ, Ilstrup DM, Harmsen WS, Tenkins GD, Patel R. Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002; 40:495-500.
18. Morishima C, Chung M, Ng KW, Brambilla DJ, Gretch DR. Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol 2004; 42:421-425.
19. Ross RS, Viazov S, Sarr S, Hoffmann S, Kramer A, Roggendorf M. Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay. J Virol Methods 2002; 101:159-168.
20. Trimoulet P, Halfon P, Pohier E, Khiri H, Chene G, Fleury H. Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol 2002; 40:2031-2036.
21. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim-van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495-503.
22. Bukh J, Purcell RH, Miller RH. Sequence analysis of the 5′ noncoding region of hepatitis C virus. Proc Natl Acad Sci U S A 1992; 89:4942-4946.
23. Mellor J, Hawkins A, Simmonds P. Genotype dependence of hepatitis C virus load measurement in commercially available quantitative assays. J Clin Microbiol 1999; 37:2525-2532.
24. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352:2609-2617.
25. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002 - June 10-12, 2002. Hepatology 2002; 36:3-20.
26. Verbot der Verwendung des HPS COBAS TaqMan HCV Test (Roche Diagnostics GmbH, 68298 Mannheim) bei der Herstellung von zellulären Blutkomponenten und gefrorenem Frischplasma (vom 11. August 2004). Bundesanzeiger Nr. 166 vom 03. September 2004, S. 19770